Applied Biosystems and GeneGo Collaborate to Advance Understanding of Tissue Gene Expression
Complete the form below to unlock access to ALL audio articles.
Applied Biosystems, an Applera Corporation business, and GeneGo, Inc. have announced a collaboration designed to enhance researchers' ability to study differential gene expression in biological pathways.
As part of the agreement, GeneGo has integrated the Applied Biosystems Tissue Gene Expression Database into its MetaCore™ data mining platform.
The combined solution facilitates microarray experiments, such as comparing gene expression changes in normal versus diseased or treated human tissues.
The Tissue Expression Database, created using the Applied Biosystems Expression Array System and Human Genome Survey Microarray, is a proprietary dataset of genome-wide gene expression values from 31 normal tissues and a Universal Human Reference RNA.
This extensive dataset can serve as a baseline reference for microarray results and a source for identifying tissue-specific genes.
Applying sensitive chemiluminescent technology, advanced bioinformatics, and a combination of public and proprietary data, the Applied Biosystems Expression Array System is designed to detect genes with specificity and sensitivity than other commercially available microarray platforms.
"Organ, tissue and cell type specificity are extremely important in human and other mammalian gene expression analysis," said Tatiana Nikolskaya, chief scientific officer and founder of GeneGo.
"The Applied Biosystems Tissue Expression Database is high quality, standardized and very well annotated data."
"We have integrated it as a tissue expression filter in our latest product release to replace the publicly available, but less consistent, UniGene data, and look forward to collaborating on additional ways to leverage our complementary solutions."
"GeneGo has a strong track record of integrating best-of-class technologies and data into its software platform to support emerging systems biology applications," said Carl Hull, vice president for the sequence detection system and microarray business units of Applied Biosystems.
"This collaboration represents a mutually beneficial way to support our respective customers in their endeavors to turn their valuable data into meaningful information in the drug discovery and development process."
